Management of Chemotherapy-Induced Thrombocytopenia: Current Status of Thrombopoietic Agents

Seminars in Hematology

Volumn 46, Issue SUPPL. 2, 2009, Pages

  Vadhan Raj, Saroj ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKR 501; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CYTOKINE; DACARBAZINE; DOXORUBICIN; ELTROMBOPAG; ETOPOSIDE; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 3; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; MESNA; MILODISTIM; NITROSOUREA DERIVATIVE; RECOMBINANT INTERLEUKIN 11; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; ROMIPLOSTIM; STEM CELL FACTOR; THROMBOPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ARTICLE; DRUG DOSE REDUCTION; HEALTH CARE COST; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

BENZOIC ACIDS; CARRIER PROTEINS; CLINICAL TRIALS AS TOPIC; HUMANS; HYDRAZINES; INTERLEUKIN-11; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; THROMBOPOIESIS;

EID: 60549096096     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.12.007     Document Type: Article

References (36)

1. Kaushansky K. The thrombocytopenia of cancer. Prospects for effective cytokine therapy. Hematol Oncol Clin North Am 10 (1996) 431-455
2. Elting L.S., Rubenstein E.B., Martin C.G., Kurtin D., Rodriguez S., Laiho E., et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19 (2001) 1137-1146
3. Avecilla S.T., Hattori K., Heissig B., Tejada R., Liao F., Shido K., et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 10 (2004) 64-71
4. + cells. Blood 82 (1993) 84-95
5. + cells. Blood 91 (1998) 830-843
6. Guerriero R., Mattia G., Testa U., Chelucci C., Macioce G., Casella I., et al. Stromal cell-derived factor 1alpha increases polyploidization of megakaryocytes generated by human hematopoietic progenitor cells. Blood 97 (2001) 2587-2595
7. Kuter D.J., and Begley C.G. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100 (2002) 3457-3469
8. Elting L.S., Cantor S.B., Martin C.G., Hamblin L., Kurtin D., Rivera E., et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 97 (2003) 1541-1550
9. Lonial S., Waller E.K., Richardson P.G., Jagannath S., Orlowski R.Z., Giver C.R., et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106 (2005) 3777-3784
10. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., and Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332 (1995) 901-906
11. Chang J. Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36 Suppl 1 (2000) S11-S14
12. Schiffer C.A., Anderson K.C., Bennett C.L., Bernstein S., Elting L.S., Goldsmith M., et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1519-1538
13. Wallace E.L., Churchill W.H., Surgenor D.M., Cho G.S., and McGurk S. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 38 (1998) 625-636
14. Cobain T.J., Vamvakas E.C., Wells A., and Titlestad K. A survey of the demographics of blood use. Transfus Med 17 (2007) 1-15
15. Brecher ME. The platelet prophylactic transfusion trigger: when expectations meet reality. Transfusion. 200; 47:188-91.
16. Demetri G.D. Targeted approaches for the treatment of thrombocytopenia. Oncologist 6 Suppl 5 (2001) 15-23
17. Gaydos L.A., Freireich E.J., and Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266 (1962) 905-909
18. Slichter S.J., and Harker L.A. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 7 (1978) 523-539
19. Benjamin R.J., and Anderson K.C. What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?. Crit Rev Oncol Hematol 42 (2002) 163-171
20. Ciurea S.O., and Hoffman R. Cytokines for the treatment of thrombocytopenia. Semin Hematol 44 (2007) 166-182
21. Tepler I., Elias L., Smith J.W., Hussein M., Rosen G., Chang A.Y., et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87 (1996) 3607-3614
22. Cairo M.S., Davenport V., Bessmertny O., Goldman S.C., Berg S.L., Kreissman S.G., et al. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br J Haematol 128 (2005) 49-58
23. Harker L.A. Therapeutic cytokine stimulation of thrombocytopoiesis. Transfus Sci 19 (1998) 149-162
24. Vadhan-Raj S., Murray L.J., Bueso-Ramos C., et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 126 (1997) 673-681
25. Basser R.L., Rasko J.E., Clarke K., Cebon J., Green M.D., Hussein S., et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348 (1996) 1279-1281
26. Fanucchi M., Glaspy J., Crawford J., Garst J., Figlin R., Sheridan W., et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336 (1997) 404-409
27. Vadhan-Raj S., Verschraegen C.F., Bueso-Ramos C., Broxmeyer H.E., Kudelka A.P., Freedman R.S., et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 132 (2000) 364-368
28. Vadhan-Raj S., Patel S., Bueso-Ramos C., Folloder J., Papadopolous N., Burgess A., et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 21 (2003) 3158-3167
29. Vadhan-Raj S., Cohen V., and Bueso-Ramos C. Thrombopoietic growth factors and cytokines. Curr Hematol Rep 4 (2005) 137-144
30. Schiffer C.A., Miller K., Larson R.A., Amrein P.C., Antin J.H., Zani V.J., et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 95 (2000) 2530-2535
31. Vadhan-Raj S., Kavanagh J.J., Freedman R.S., Folloder J., Currie L.M., Bueso-Ramos C., et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet 359 (2002) 2145-2152
32. Wang B., Nichol J.L., and Sullivan J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76 (2004) 628-638
33. Jenkins J.M., Williams D., Deng Y., Uhl J., Kitchen V., Collins D., et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109 (2007) 4739-4741
34. Desjardins R.E., Tempel D.L., Lucek R., and Kuter D.J. Single and multiple oral doses of AKR-501 (YM477) increases the platelet count in healthy volunteers [abstract 477]. Blood 108 (2006) 145a
35. SB-497115 (oral thrombopoietin receptor agonist) versus placebo in adult cancer patients receiving chemotherapy. http://clinicaltrials.gov/ct2/show/NCT00102726 Accessed September 11, 2008.
36. Dose evaluation study of oral eltrombopag in patients with sarcoma receiving the adriamycin and ifosfamide regimen. http://clinicaltrials.gov/ct2/show/NCT00358540 Accessed September 11, 2008.